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Background: The efficacy of the widely used albendazole against the soil-transmitted helminth Trichuris tri-
chiura is limited; yet optimal doses, which may provide increased efficacy, have not been thoroughly investi-
gated to date.
Methods: A randomized-controlled trial was conducted in Co^te d’Ivoire with preschool-aged children (PSAC),
school-aged children (SAC), and adults infected with T. trichiura. Participants were randomly assigned
(1:1:1:1) using computer-generated randomization. PSAC were randomized to 200 mg, 400 mg, 600 mg of
albendazole or placebo. SAC and adults were randomized to 400 mg, 600 mg, 800 mg of albendazole or pla-
cebo. The primary outcome was cure rates (CRs) against trichuriasis. Secondary outcomes were T. trichiura
egg reduction rates (ERRs), safety, CRs and ERRs against other soil-transmitted helminths. Outcome assessors
and the trial statistician were blinded. Trial registration at ClinicalTrial.gov: NCT03527745.
Findings: 111 PSAC, 180 SAC, and 42 adults were randomized and 86, 172, and 35 provided follow-up stool
samples, respectively. The highest observed CR among PSAC was 27¢8% (95% CI: 9¢7%53¢5%) in the 600 mg
albendazole treatment arm. The most efficacious arm for SAC was 600 mg of albendazole showing a CR of
25¢6% (95% CI: 13¢5%41¢2%), and for adults it was 400 mg of albendazole with a CR of 55¢6% (95% CI:
21¢2%86¢3%). CRs and ERRs did not differ significantly among treatment arms and flat dose-responses were
observed. 17¢9% and 0¢4% of participants reported any adverse event at 3 and 24 h follow-up, respectively.
Interpretation: Albendazole shows low efficacy against T. trichiura in all populations and doses studied,
though findings for PSAC and adults should be carefully interpreted as recruitment targets were not met.
New drugs, treatment regimens, and combinations are needed in the management of T. trichiura infections.
Funding: Bill and Melinda Gates Foundation.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license.
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Almost a quarter of the world’s population is infected with soil-
transmitted helminths (STHs): Trichuris trichiura (whipworm), Ascaris
lumbricoides (roundworm), and Ancylostoma duodenale or Necator
americanus (hookworms) [1]. STH infections account for a burden of
over 1¢9 million disability-adjusted life-years (DALYs) per year with
trichuriasis accounting for 213 thousand DALYs [2]. Greatest at risk
for infection are those living without access to potable water andliving with inadequate sanitation in tropical climates [35]. Heavy
intensity infections may lead to diarrhea, abdominal pain, inflamma-
tion, obstruction and, if untreated, nutrition and immune system
impairment [3,6].
Preventive chemotherapy (PC), recommended by the World
Health Organization (WHO) is the periodic administration of anthel-
mintic drugs through mass drug administration (MDA) campaigns
[1]. PC has been successful in reducing the number of STH infections
and reducing the burden of disease (especially moderate and heavy
infections) by averting an estimated 61 thousand DALYs from 2010
to 2015 [7,8]. Current recommendations for MDA of first-line treat-
ment include monotherapy of 400 mg of albendazole or 500 mg of
Research in context
Evidence before this study
A literature review was conducted in PubMed searching for
“Trichuris” and “albendazole” from inception to January 1,
2020. Different dosages and regimens of albendazole have been
tested against T. trichiura; however, a thorough dose-finding
study has not been done to date for preschool-aged children,
school-aged children, and adults.
Added value of this study
This is the first multi-cohort, randomized-controlled trial con-
ducted to determine the optimal dose of albendazole in several
age groups targeted by treatment recommendations of the WHO.
Based on the results of this trial in Co^te d’Ivoire, it can be con-
cluded that the current recommended dose of 400 mg of albenda-
zole is not efficacious and higher doses do not provide any added
benefit.
Implications of all the available evidence
Treatment with a single dose of the benzimidazoles annually or
biannually in areas of STH prevalence 20% is the current key
recommendations for the control of soil-transmitted hel-
minths; however, efficacy of the drugs against trichuriasis is
very low. Evidence from this trial confirms that albendazole,
even at higher doses, is insufficient for treating T. trichiura
infections; and, therefore novel treatments or combination
therapy should be considered as part of control efforts to con-
trol and ultimately eliminate STHs.
2 C. Patel et al. / EClinicalMedicine 22 (2020) 100335mebendazole once or twice a year targeting children, girls and
women of reproductive age, and women after the first trimester of
pregnancy in settings where STH prevalence is 20% [1,9]. However,
albendazole and mebendazole show limited efficacy against T. tri-
chiura (cure rates of 30% and 42%, respectively) [9,10].
To date, the optimal dose for albendazole has not been deter-
mined and 400 mg is the standard dose regardless of age and/or
weight [1,11]. Though a driver of efficacy has not been identified,
hypothetically, a higher dose may be needed for school-aged children
(SAC) and adults. Different doses of albendazole have been tested for
efficacy against T. trichiura, but a formal dose-response relationship
has not been conducted [12]. The objective of this trial was for the
first time to determine the efficacy and safety of ascending doses of
albendazole against T. trichiura in three population cohorts (pre-
school-aged children (PSAC), SAC, and adults).2. Methods
2.1. Study design
A phase two, parallel, randomized, placebo-controlled, dose-find-
ing trial was conducted in seven villages near the town of Azaguie in
the Agboville department of southern Co^te d’Ivoire from October 23,
2018 to January 12, 2019. PSAC 25 years of age, SAC 612 years of
age, and adults over the age of 21 years were invited to participate in
the trial. It was decided not to include community members aged
1320 years for two reasons: no differences between teenagers and
adults were expected and teenage community members are the most
transient population in remote villages based on our own previous
experience. Ethical clearance was obtained from the Comite National
d’Ethique des Sciences de la Vie et de la Sante (July 3, 2018, referenceNo. 089-18//MSHP/CNESVS-km), and the Ethics Committee of North-
western and Central Switzerland (July 20, 2018, Nr 2018-00545).
2.2. Participants
Prior to enrolment, an information session explaining the pur-
pose, procedure, benefits, and risks of the trial was conducted in each
of the seven villages for all community members. Written informed
consent was obtained from all participants and/or parents and guard-
ians of the children after they had attended the information session.
Additionally, SAC provided written assent.
PSAC, SAC, and adults were eligible if they provided two stool
samples and were positive for T. trichiura. Only PSAC with T. trichiura
infection intensities 60 eggs per gram of stool (EPG) and SAC and
adults with T. trichiura infection intensities 100 EPG were included
in the trial. Excluded from the trial were those with acute or uncon-
trolled systemic illnesses (e.g., severe anemia defined as hemoglobin
<8.0 g/dl, infection, clinical malaria) as assessed by a medical doctor
upon initial clinical assessment and liver function tests, those who
had received anthelmintic within the previous 4 weeks, those who
were allergic to benzimidazoles, and pregnant or breastfeeding
women.
2.3. Randomization and masking
Study participants eligible for treatment were randomly assigned
to one of the treatment arms using a computer-generated, stratified
block randomization code. A random allocation sequence with vary-
ing random blocks of 4 and 8 stratified by 2 levels of baseline infec-
tion intensity (light and moderate/heavy T. trichiura) according to
WHO guidelines was provided by a statistician not involved in
recruitment or data collection [13]. Since so few moderate and high
infections are present in the setting, it was decided to combine these
two levels of intensity into one stratum. PSAC were 1:1:1:1 random-
ized to placebo or albendazole at 200 mg, 400 mg, or 600 mg. SAC
and adults were 1:1:1:1 randomized to placebo or albendazole at
400 mg, 600 mg, or 800 mg. Study-site investigators were aware of
the study group assignment, whereas outcome assessors and the trial
statistician were masked to group assignment. Participants might
have recognized the study group assignment due to the number of
tablets administered.
2.4. Procedures
Children and adults provided two stool samples collected on two
different days after providing name, age, and sex in a village-wide
census. Duplicate Kato-Katz thick smears (41¢7 mg each) were pre-
pared from each sample and examined for T. trichiura, Ascaris lumbri-
coides, and hookworm eggs [14]. Egg counts were recorded by
experienced technicians and classified as light, moderate, or heavy
[14]. An independent quality control was conducted for 10% of the
slides prepared with results considered correct if: (i) no difference in
presence/absence of T. trichiura, A. lumbricoides, and hookworm; (ii)
egg counts were +/10 eggs for counts 100 eggs or +/20% for
counts >100 eggs (for each species separately) [15].
Before treatment, eligible children and adults were examined
physically and questioned for clinical symptoms by a trial physician.
Height using a stadiometer, weight using a scale, and temperature
using an ear thermometer were collected by trial nurses. In addition,
venous blood samples were taken at baseline to assess organ toxicity,
complete blood count, and hepatic/renal function, while capillary
blood samples using the finger-prick method were used to measure
hemoglobin levels (HemoCue 301) and diagnose malaria through a
rapid test (ICT Malaria P.f. Antigen Test, ICT Diagnostics).
On the day of treatment, enrolled participants were given potable
water and a high-fat breakfast before receiving either albendazole or
C. Patel et al. / EClinicalMedicine 22 (2020) 100335 3placebo orally with water. Active adverse event assessment using a
questionnaire was conducted at 3 h, 24 h, and 1421 days after treat-
ment. Participants were asked about the occurrence and intensity of
headache, abdominal pain, nausea, vomiting, diarrhea, itching, aller-
gic reactions, and any other symptom; moreover, temperature was
taken to assess fever. Between 14 and 21 days post-treatment, treat-
ment efficacy was assessed by collecting and examining two addi-
tional stool samples as described above. At the end of the trial, all
participants and excluded children/adults remaining positive for any
helminth infection were treated with 400 mg of albendazole in accor-
dance with WHO guidelines [1].
2.5. Outcomes
The primary outcome is cure rate (CR) against T. trichiura at
1421 days post-treatment. Secondary outcomes include egg reduc-
tion rate (ERR) against T. trichiura, CRs and ERRs against A. lumbri-
coides and hookworm, and drug safety. Drug safety was assessed at
3 h, 24 h, and 1421 days after treatment.
2.6. Sample size
The main aim of this trial is to determine the dose-response rela-
tionship of albendazole against T. trichiura. A series of simulationsFig. 1. a: PSAC participant flow-chart. Abbreviations: EPG, eggs per gram; PSAC, preschool-
preschool-aged children. c: Adults participant flow-chart. Abbreviations: EPG, eggs per gramwere carried out to determine the required sample size. We assumed
a true CR of 5%, 10%, 20%, 30%, and 40% against T. trichiura and a loss
to follow-up of 5%. We estimated that enrolling 40 participants per
arm will be sufficient to predict the dose response curve with a preci-
sion of about 10% points [16]. See supplementary material for details
in sample size determination.
2.7. Statistical analyses
All data were collected on paper forms and entered twice into a
database (Access 2010, Microsoft), cross-checked using the Data
Compare utility of EpiInfo, version 3.5.4 (Centers for Disease Control
and Prevention, Atlanta, GA, SA), and any discrepancies corrected by
consulting the hard copy. Data management and descriptive results
were done in Stata, version 15 (StataCorp, College Station, TX, USA),
and the estimation of the dose-response curve was performed in R,
version 3.5.1 (www.r-project.org).
An available-case analysis was performed according to the
intention-to-treat principle using a full analysis set of all random-
ized participants providing any follow-up data. A per protocol
analysis was planned according to the protocol. Since there were
no protocol deviations the per protocol population was identical to
the available case population. CRs were calculated as the percent-
age of egg-positive participants at baseline who become egg-aged children. b: SAC participant flow-chart. Abbreviations: EPG, eggs per gram; SAC,
.
Fig. 1 Continued.
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mean egg counts from the quadruplicate Kato-Katz thick smears
and multiplying this number by a factor of 24. The ERR was calcu-
lated with the following formula:
ERR ¼ 1
1
n e
P
log EPGfollowupþ1ð Þ1
1
n e
P
log EPGbaselineþ1ð Þ1
Geometric mean egg counts were calculated for the different
treatment arms before and after treatment to assess the correspond-
ing ERRs. Bootstrap resampling method with 5000 replicates was
used to calculate 95% confidence intervals (CIs) for ERRs point esti-
mates. ERRs were not calculated when too few infections were
observed; moreover, 95% CIs were not calculated in cases of too small
sample sizes for other helminth infections.
The hyperbolic Emax dose-response model was fitted using the
DoseRange packages version 0.917 with the coefficients and the
variance-covariance matrix estimates from a logistic regression. The
analysis code is similar to the one used for the sample size simula-
tions (Supplementary Material). The halfmaximaleffect dose
(ED50) was estimated as half of the maximal placebo-adjusted effect
on logit scale and afterwards back-transformed to probability (i.e.,
cure rate) scale.
Adverse events were descriptively evaluated as the number and
proportion of participants reporting adverse events before and after
treatment. The trial is registered at ClinicalTrials.gov (NCT03527745).2.8. Role of the funding source
The funder of the study had no role in the study design, data col-
lection, data analysis, data interpretation, or writing of the report.
The corresponding author had full access to all the data in the study
and had final responsibility for the decision to submit for publication.3. Results
3.1. Baseline characteristics
Participants were recruited for the trial between October 23, 2018
and December 1, 2018. Despite an intensive screening effort, the tar-
geted sample size (160 participants in each age cohort) was not
reached for PSAC (69%) and adults (26%). A total of 2330 (493 PSAC,
850 SAC, and 987 adults) were screened for eligibility. Of those
screened, 137 PSAC, 273 SAC, and 56 adults were invited for clinical
examination, while 1607 were negative for T. trichiura and 50 PSAC,
112 SAC, and 95 adults had too low infection intensities. Of those
invited to clinical examination, 26 PSAC, 40 SAC, and 14 adults either
refused participation, were excluded based on eligibility criteria, or
absent on treatment day. 53 eligible SAC children were oversampled
and not enrolled in the trial. A total of 111 PSAC, 180 SAC, and 42
adults were randomly assigned to one of four treatment arms
(Fig. 1ac). At follow-up, 25 PSAC (22¢5%), 7 SAC (3¢9%), and 7 adults
(16¢7%) did not provide stool samples or were absent.
Baseline demographic and parasitological characteristics of PSAC,
SAC, and adults included in the trial are presented in Table 1. Age,
weight, height, and infection intensity were balanced across arms
within the PSAC and SAC cohorts. In PSAC and adult cohorts, there
were more female than male participants across all arms. Among
SAC, there were more females in the placebo group in comparison to
those receiving 400 mg of albendazole (25 vs 15); all other arms
were balanced in terms of sex. The majority of infections were of light
intensity (ranging 6781% across arms) in all three age cohorts. In
total, 22 PSAC, 57 SAC, and 3 adults had moderate or heavy intensity
infections. There were very few co-infections with A. lumbricoides
and/or hookworm: 20 PSAC, 54 SAC, and 6 adults were infected with
A. lumbricoides and 1 PSAC, 7 SAC, and 2 adults were infected with
hookworm.
Fig. 1 Continued.
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CRs and ERRs of each arm against T. trichiura are shown in Table 2
for SAC, while results for PSAC and adults can be found in Supple-
mentary Table S1. The Emax model predicted a maximal CR (Emax) of
24¢7% and an ED50 at 118 mg. This predicted doseresponse curve
showed a plateau at approximately 500 mg (Fig. 2) with predicted
CRs for the investigated doses of 6¢5% (95% CI: 2¢1%18¢3%) in the
placebo group and 18¢7% (95% CI: 9¢7%32¢9%), 20¢2% (95% CI:
13¢9%28¢4%), and 21¢1% (95% CI: 12¢0%34¢6%) at 400 mg, 600 mg,
and 800 mg, respectively. The observed CRs were close to the pre-
dicted values, except at 600 mg where the observed CR was
5.4%points higher (25¢6%, 95% CI: 13¢5%41¢2%). Observed ERRs
plateaued already at the first investigated dose (400 mg, ERR: 82¢0%,
95% CI: 67¢8%90¢5%).
Observed CRs among PSAC were similar across all arms ranging
from 9¢5% (95% CI: 1¢2%30¢4%) to 27¢8% (95% CI: 9¢7%53¢5%). The
corresponding geometric ERRs found were also similar across treat-
ment arms ranging from 63¢8% in the 200 mg albendazole arm to
88¢5% in the 600 mg albendazole arm. Observed CRs for adults were
55¢6% (95% CI: 21¢2%86¢3%), 50¢0% (95% CI: 15¢7%84¢3%), 27¢3%
(95% CI: 6¢0%61¢0%), 14¢3(95% CI: 0¢4%57¢9%) for albendazole at
400 mg, 600 mg, 800 mg, and placebo, respectively. The geometric
ERRs ranged from 85¢2% (placebo arm) to 97¢7% (400 mg of albenda-
zole arm).
Supplementary Table S2 presents the proportions of participants
cured within each treatment arm by sex.3.3. Efficacy against hookworm and A. lumbricoides
Data on CRs and ERRs against other helminth infections for PSAC,
SAC, and adults are presented in Supplementary Table S3. Forhookworm, 7 out of the 10 infections with follow-up data were cured
with any dose of albendazole across all treatment arms in all cohorts.
For roundworm, CRs ranged between 66¢7%100% for PSAC given
albendazole and 0% for PSAC given placebo. For SAC, CRs ranged from
84¢6%100% in active treatment arms and 38¢5% in the placebo arm.
All adults with A. lumbricoides infections were cured receiving either
400 mg or 800 mg of albendazole. Geometric and arithmetic ERRs
had similarly large ranges for PSAC and SAC for all active treatment
groups (placebo groups were considerably lower), and 100% for the
adults cured by 400 mg or 800 mg of albendazole.
3.4. Safety
At baseline 102 PSAC, 172 SAC, and 42 adults were questioned for
symptoms. A total of 84 (26¢6%) participants reported mild symptoms
at baseline, such as abdominal pain (11¢4%), headache (11¢1%), itching
(5¢4%), and diarrhea (4¢4%).
104 PSAC, 175 SAC, and 41 adults were interviewed at 3 h post-
treatment for adverse events and 86 PSAC, 154 SAC, and 32 adults
were interviewed at 24 h post-treatment for adverse events. After
treatment the proportion of reporting any adverse events was 17¢9%
and 0¢4% at 3 and 24 h follow-up, respectively. Numbers of partici-
pants reporting each adverse event is reported in Table 3.
After treatment of 200 mg of albendazole, one participant (PSAC)
reported a case of clinical malaria requiring inpatient hospitalization
due to a serious adverse event. The participant received anti-malaria
treatment and was released from the hospital within 24 h. No allergic
reaction to any treatment arm was observed.
4. Discussion
The WHO has approved five different drugs and combinations
against STH infections, of which albendazole is the most widely
Table 1
Baseline characteristics of participants. Numbers represent N (%) unless otherwise stated. Abbreviations: ALB, albendazole; EPG, eggs per gram; IQR, interquartile range; PLAC, placebo; PSAC, preschool-aged children; SAC, school-aged children;
SD, standard deviation.
PSAC SAC Adults
ALB 200 mg
(n = 27)
ALB 400 mg
(n = 30)
ALB 600 mg
(n = 27)
PLAC (n = 27) ALB 400 mg
(n = 45)
ALB 600 mg
(n = 46)
ALB 800 mg
(n = 43)
PLAC (n = 46) ALB 400 mg
(n = 11)
ALB 600 mg
(n = 9)
ALB 800 mg
(n = 12)
PLAC
(n = 10)
Mean (SD) age (years) 4¢0 (0¢9) 3¢8 (1¢1) 4¢0 (0¢9) 4¢1 (0¢9) 8¢9 (1¢9) 8¢7 (2¢0) 8¢8 (1¢8) 8¢9 (1¢9) 40¢5 (11¢9) 36¢6 (12¢2) 44¢8 (15¢9) 44¢4 (12¢3)
Females 18 (67%) 16 (53%) 18 (67%) 16 (59%) 15 (33%) 19 (41%) 17 (40%) 25 (54%) 9 (82%) 7 (78%) 8 (67%) 6 (60%)
Mean (SD) weight (kg) 15¢1 (2¢9) 14¢8 (2¢2) 15¢1 (2¢3) 14¢6 (2¢5) 26¢2 (6¢5) 24¢1 (5¢7) 24¢3 (4¢1) 25¢3 (6¢6) 54¢0 (7¢6) 60¢5 (8¢9) 57¢0 (6¢0) 57¢4 (9¢7)
Mean (SD) height (cm) 97¢2 (9¢5) 99¢2 (10¢4) 97¢6 (10¢1) 97¢5 (10¢7) 126¢8 (10¢5) 123¢7 (11¢4) 125¢0 (8¢8) 125¢8 (12¢2) 157¢5 (5¢3) 158¢8 (5¢8) 158¢5 (8¢3) 160¢1 (8¢5)
Trichuris trichiura
Median EPG [IQR] 264
[96558]
210
[144510]
228
[150726]
216
[120438]
426
[1921266]
507
[1861134]
414
[1621116]
387
[2221068]
168
[114504]
156
[114288]
195
[150402]
138
[114270]
EPG geometric mean 303¢4 303¢9 328¢5 371¢7 538¢6 510¢3 501¢1 521¢4 257¢4 204¢8 272¢8 173¢0
Infection intensity
Light (1999 EPG) 22 (81%) 24 (80%) 21 (78%) 22 (81%) 30 (67%) 31 (67%) 30 (70%) 32 (70%) 10 (91%) 9 (100%) 10 (83%) 10 (100%)
Moderate
(10009999 EPG)
5 (19%) 5 (17%) 6 (22%) 4 (15%) 15 (33%) 15 (33%) 12 (28%) 14 (30%) 1 (9%) 0 (0%) 2 (17%) 0 (0%)
Heavy (10,000
EPG)
0 (0%) 1 (3%) 0 (0%) 1 (4%) 0 (0%) 0 (0%) 1 (2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Hookworm
Infected children 0 1 0 0 1 2 3 1 1 0 0 1
Ascaris lumbricoides
Infected children 8 5 3 4 18 10 13 13 3 0 3 0
Median EPG [IQR] 7929
[312310,395]
2118
[14286144]
1938
[3010,530]
6216
[72312,987]
5526
[69017,160]
14,823
[196225,050]
7668
[252014,952]
528
[21013,122]
13,500
[390618,954]
1068
[16812,600]
EPG geometric mean 3190¢4 2163¢3 857¢6 2606¢3 2752¢7 4418¢1 3241¢1 1078¢3 9998¢5 1314¢5
Infection intensity
Light (14999
EPG)
2 (25%) 3 (60%) 2 (67%) 2 (50%) 8 (44%) 4 (40%) 6 (46%) 8 (62%) 1 0 2 0
Moderate
(500049,999
EPG)
6 (75%) 2 (40%) 1 (33%) 2 (50%) 9 (50%) 6 (60%) 7 (54%) 5 (38%) 2 0 1 0
Heavy (50,000
EPG)
0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (6%) 0 (0%) 0 (0%) 0 (0%) 0 0 0 0
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Table 2
Observed and predicted cure rates and egg reduction rates against Trichuris trichiura of SAC at 3 weeks follow-up. Abbreviations: ALB, albendazole; CI, confidence interval; CR, cure
rate; EPG, eggs per gram; ERR, egg reduction rate; PLAC, placebo; SAC, school-aged children.
ALB 400 mg ALB 600 mg ALB 800 mg PLAC
Positive before treatment (n) 43 43 41 46
Cured after treatment (n) 7 11 7 3
Observed CR [95% CI] 16¢3 [6¢8, 30¢7] 25¢6 [13¢5, 41¢2] 17¢1 [7¢2, 32¢1] 6¢5 [1¢4, 17¢9]
Predicted CR [95% CI] 18¢7 [9¢7, 32¢9] 20¢2 [13¢9, 28¢4] 21¢1 [12¢0, 34¢6] 6¢5 [2¢1, 18¢3]
EPG geometric mean
Baseline 542¢3 517¢3 507¢9 521¢9
3 weeks follow-up 97¢4 59¢9 108¢1 230¢1
Observed ERR [95% CI] 82¢0 [67¢8, 90¢5] 88¢4 [74¢8, 94¢9] 78¢7 [60¢5, 89¢0] 55¢9 [26¢1, 75¢2]
EPG arithmetic mean
Baseline 1094¢4 955¢3 1247¢4 1094¢0
3 weeks follow-up 545¢2 687¢1 893¢6 1009¢8
Observed ERR [95% CI] 50¢2 [21¢5, 67¢9] 28¢1 [49¢5, 69¢6] 28¢4 [2¢6, 54¢3] 7¢7 [46¢0, 43¢1]
C. Patel et al. / EClinicalMedicine 22 (2020) 100335 7used [11]. Although albendazole has been licensed for human use
since 1982, there have been limited studies of its efficacy against
T. trichiura in PSAC and adults; and, the optimal dosages of the drug
have not been determined in humans [3,10,17]. There are many
studies on the single dose of 400 mg recommended by the WHO,
which reveal albendazole has low efficacy against T. trichiura [6,9].
Despite the lack of effective alternative treatment against trichuria-
sis, to date only a handful of studies have been conducted on higher
dosages and dose-finding studies in different age-groups have not
been carried out [12,18,19]. As national control programs move
towards elimination, treatment of all age groups becomes increas-
ingly important to prevent spread of infection; therefore, optimal
doses for PSAC, SAC, and adults are necessary [6].
This trial revealed that there is no remarkable dose response of
albendazole against T. trichiura in PSAC, SAC, and adults within the
observed range. The current recommended dose of 400 mg for SAC is
not efficacious against T. trichiura and higher doses of 600 mg or
800 mg do not increase CRs or provide a greater reduction in infec-
tion intensity. These results are confirmed by the predictions of the
Emax model, which show no visual difference between CRs betweenFig. 2. CRs and ERRs predicted by the hyperbolic Emax model. Dotted lines represent the dos
numbers present the predicted CRs and ERRs for the investigated doses. Gray circles with b
spond to the 95% confidence intervals. Predicted and observed estimates are similar in the pldoses of albendazole for SAC. Furthermore, only the 400 mg dose of
albendazole has an arithmetic ERR slightly surpassing the proposed
50% arithmetic ERR by the WHO [20]. Though recruitment was lim-
ited for PSAC and adults, a similar conclusion is plausible as CRs for
albendazole were low in all treatment arms. Though this study was
conducted in a single country only, we are convinced that the find-
ings of this trial are generalizable to wider populations as possible
confounding factors were limited (e.g., a rigorous diagnostic proce-
dure was used). Moreover, strain differences resulting in varying
albendazole susceptibility are not to be expected. In one of our recent
trials, an albendazole combination with oxantel pamoate found simi-
lar CRs against STHs in both Laos and a nearby setting in Co^te d’Ivoire
[21].
It is impossible to conclude if 400 mg is the optimal dose for SAC
and adults, since a 200 mg dose of albendazole was not tested. A flat
dose response was not anticipated for any cohort, so the dose of
200 mg of albendazole was not included as a treatment arm when
the trial was designed. In PSAC, however, a dose 200 mg of albenda-
zole provided a similar efficacy and ERR as albendazole at 400 mg,
hinting that the recommended higher dose does not provide anye-response curve and the hatched area corresponds to the 95% confidence band. White
lack numbers represent the observed dose group CRs and the gray vertical lines corre-
acebo group; therefore, only one number is provided.
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8 C. Patel et al. / EClinicalMedicine 22 (2020) 100335benefit in this age group for T. trichiura infection. However, this find-
ing would need to be confirmed in a follow-up study as our recruit-
ment targets for this age group were not met.
More females were recruited into the trial than males. Additional
analysis stratified by sex showed a difference in CRs between
females and males. Females and males had similar baseline infection
intensities (Table 1) and it was confirmed through pharmacokinetic
analyses that drug exposure of albendazole was similar across sex
regardless of treatment arm (data not shown). Further studies will
need to assess whether this difference may be due to chance or to
evaluate the underlying reasons for this finding.
The findings of this trial are comparable to others on albendazole
in the literature. In a recent network meta-analysis, Moser and col-
leagues found that 400 mg of albendazole had a limited efficacy
against T. trichiura with CRs having decreased from 38¢6% in 1999 to
16.4% in 2015 [10]. However, most of the trials included in the analy-
sis limited their study populations to SAC [10]. In comparison,
mebendazole was found to have a slightly higher CR (42¢1%) with a
single dose and higher CRs when given at 100 mg twice/day for
3 days (CR=63%) [10,19].
In 2000, Horton et al. summarized in a literature review that
increasing the single dosage and using repeated doses improves the
efficacy of albendazole against T. trichiura [12]. In contrast, in our
study increased single dosages did not provide improved efficacy
against T. trichiura. Differences could be attributed to decreasing effi-
cacy over the last two decades, differing study design, or geographic
area [12]. The scope of this trial did not include evaluation of repeated
doses of albendazole, which shows mixed results in humans and
would be more difficult to administer through control programs
[19,22].
A low number of study participiants due to low prevalence in
adults, and to a lesser extent, in PSAC, is a main limitation of our trial.
Only 4¢3% of adults screened were included in the trial as the major-
ity (84¢7%) of adults screened were found to be T. trichiura negative.
The limited sample size of adults (n = 35 across four treatment arms)
might have triggered higher CRs for the 400 mg and 600 mg treat-
ment arms (55¢6% and 50¢0%, respectively). For PSAC, 62¢1% of
screened PSAC were negative for T. trichiura infection and only
22¢5% of PSAC participated in the trial.
In conclusion, albendazole is not an effective treatment of T. tri-
chiura even at the highest doses administered. Recently, a few trials
have shown that combination therapy of albendazole and ivermectin
is more efficacious against trichuriasis compared to monotherapy
with the added benefit of Strongyloides stercoralis control [23]. This
trial confirms to reduce the burden of STHs, new first-line treat-
ments are needed, or combination therapy should be administered.
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